PMC:7293470 / 4047-4366 JSONTXT

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T130","span":{"begin":80,"end":83},"obj":"GO:0042611"},{"id":"T131","span":{"begin":88,"end":97},"obj":"CHEBI:59132;CHEBI:59132"},{"id":"T132","span":{"begin":139,"end":142},"obj":"GO:0042611"},{"id":"T133","span":{"begin":154,"end":161},"obj":"CHEBI:59132;CHEBI:59132"},{"id":"T134","span":{"begin":171,"end":178},"obj":"CL:0000084"},{"id":"T135","span":{"begin":184,"end":195},"obj":"GO:0006412"},{"id":"T136","span":{"begin":211,"end":216},"obj":"SP_6;NCBITaxon:9606"},{"id":"T137","span":{"begin":292,"end":295},"obj":"GO:0042611"},{"id":"T28841","span":{"begin":80,"end":83},"obj":"GO:0042611"},{"id":"T93931","span":{"begin":88,"end":97},"obj":"CHEBI:59132;CHEBI:59132"},{"id":"T69769","span":{"begin":139,"end":142},"obj":"GO:0042611"},{"id":"T81989","span":{"begin":154,"end":161},"obj":"CHEBI:59132;CHEBI:59132"},{"id":"T41673","span":{"begin":171,"end":178},"obj":"CL:0000084"},{"id":"T85672","span":{"begin":184,"end":195},"obj":"GO:0006412"},{"id":"T81660","span":{"begin":211,"end":216},"obj":"SP_6;NCBITaxon:9606"},{"id":"T64396","span":{"begin":292,"end":295},"obj":"GO:0042611"}],"text":"As partial TCR agonists these constructs, containing various disease-associated MHC and antigenic peptide components, could indeed inhibit MHC-restricted antigen specific T cells, but translation of RTL1000 for human use in a Phase 1 clinical trial (showing safety and tolerability) required MHC-matched recipients [7]."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T53","span":{"begin":80,"end":83},"obj":"Body_part"},{"id":"T54","span":{"begin":139,"end":142},"obj":"Body_part"},{"id":"T55","span":{"begin":173,"end":178},"obj":"Body_part"},{"id":"T56","span":{"begin":292,"end":295},"obj":"Body_part"}],"attributes":[{"id":"A53","pred":"fma_id","subj":"T53","obj":"http://purl.org/sig/ont/fma/fma84079"},{"id":"A54","pred":"fma_id","subj":"T54","obj":"http://purl.org/sig/ont/fma/fma84079"},{"id":"A55","pred":"fma_id","subj":"T55","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A56","pred":"fma_id","subj":"T56","obj":"http://purl.org/sig/ont/fma/fma84079"}],"text":"As partial TCR agonists these constructs, containing various disease-associated MHC and antigenic peptide components, could indeed inhibit MHC-restricted antigen specific T cells, but translation of RTL1000 for human use in a Phase 1 clinical trial (showing safety and tolerability) required MHC-matched recipients [7]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T65","span":{"begin":98,"end":105},"obj":"http://purl.obolibrary.org/obo/PR_000018263"},{"id":"T66","span":{"begin":171,"end":178},"obj":"http://purl.obolibrary.org/obo/CL_0000084"},{"id":"T67","span":{"begin":211,"end":216},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T68","span":{"begin":224,"end":225},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"As partial TCR agonists these constructs, containing various disease-associated MHC and antigenic peptide components, could indeed inhibit MHC-restricted antigen specific T cells, but translation of RTL1000 for human use in a Phase 1 clinical trial (showing safety and tolerability) required MHC-matched recipients [7]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T72","span":{"begin":15,"end":23},"obj":"Chemical"},{"id":"T73","span":{"begin":98,"end":105},"obj":"Chemical"},{"id":"T74","span":{"begin":154,"end":161},"obj":"Chemical"}],"attributes":[{"id":"A72","pred":"chebi_id","subj":"T72","obj":"http://purl.obolibrary.org/obo/CHEBI_48705"},{"id":"A73","pred":"chebi_id","subj":"T73","obj":"http://purl.obolibrary.org/obo/CHEBI_16670"},{"id":"A74","pred":"chebi_id","subj":"T74","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"}],"text":"As partial TCR agonists these constructs, containing various disease-associated MHC and antigenic peptide components, could indeed inhibit MHC-restricted antigen specific T cells, but translation of RTL1000 for human use in a Phase 1 clinical trial (showing safety and tolerability) required MHC-matched recipients [7]."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T14","span":{"begin":184,"end":195},"obj":"http://purl.obolibrary.org/obo/GO_0006412"}],"text":"As partial TCR agonists these constructs, containing various disease-associated MHC and antigenic peptide components, could indeed inhibit MHC-restricted antigen specific T cells, but translation of RTL1000 for human use in a Phase 1 clinical trial (showing safety and tolerability) required MHC-matched recipients [7]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T20","span":{"begin":0,"end":319},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"As partial TCR agonists these constructs, containing various disease-associated MHC and antigenic peptide components, could indeed inhibit MHC-restricted antigen specific T cells, but translation of RTL1000 for human use in a Phase 1 clinical trial (showing safety and tolerability) required MHC-matched recipients [7]."}

{"project":"LitCovid-PubTator","denotations":[{"id":"196","span":{"begin":80,"end":83},"obj":"Gene"},{"id":"197","span":{"begin":292,"end":295},"obj":"Gene"},{"id":"208","span":{"begin":211,"end":216},"obj":"Species"},{"id":"213","span":{"begin":139,"end":142},"obj":"Gene"}],"attributes":[{"id":"A196","pred":"tao:has_database_id","subj":"196","obj":"Gene:3107"},{"id":"A197","pred":"tao:has_database_id","subj":"197","obj":"Gene:3107"},{"id":"A208","pred":"tao:has_database_id","subj":"208","obj":"Tax:9606"},{"id":"A213","pred":"tao:has_database_id","subj":"213","obj":"Gene:3107"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"As partial TCR agonists these constructs, containing various disease-associated MHC and antigenic peptide components, could indeed inhibit MHC-restricted antigen specific T cells, but translation of RTL1000 for human use in a Phase 1 clinical trial (showing safety and tolerability) required MHC-matched recipients [7]."}